Back to Results
First PageMeta Content
Health / Pharmacology / Design of experiments / Respiratory therapy / Bioethics / Spirometry / Placebo / Asthma / Clinical trial / Medicine / Science / Clinical research


N205626 Fluticasone Statistical BPCA
Add to Reading List

Open Document

File Size: 1,94 MB

Share Result on Facebook

City

Reference / /

Company

GlaxoSmithKline / Special/Subgroup / FF 100 OD FP 250 BD / /

Event

FDA Phase / Product Issues / Product Recall / /

IndustryTerm

combination product / treatment of asthma symptoms / combination products / control / /

MedicalCondition

COPD / shortness of breath / pulmonary function / persistent asthma / chronic obstructive pulmonary disease / common chronic lung disease / coughing / Allergy / chest tightness / Introduction Overview Background Asthma / MS / severe asthma / wheezing / asthma / /

Organization

US Department of Health and Human Services / Division of Pulmonary / Allergy / and Rheumatology Products Clinical Team / Standard Biometrics Division / Division of Pulmonary / FDA / Food and Drug Administration Center for Drug Evaluation / /

Person

Tracy Kruzick / Gregory Levin / Thomas Permutt / Banu Karimi-Shah / David Petullo / Nina Ton Keywords / /

Position

Executive / Medical Team Leader Pro ject Manager / /

Product

FEV1 / Patient / visit / Dropouts Prior to / albuterol / Fluticasone Furoate Inhalation Powder / FFA109687 / HZA106827 / Fluticasone / /

ProgrammingLanguage

FP / /

PublishedMedium

Baseline / /

Technology

Drug Development / /

SocialTag